Genetically engineered oncolytic immunotherapy with a multiple-pronged attack on cancer.
Learn More
CG Oncology Announces First Patient Dosed in Phase 1b Study of Oncolytic Immunotherapy CG0070 in Combination with OPDIVO® (nivolumab) in Muscle-Invasive Bladder Cancer
CG Oncology Announces License and Commercialization Agreement with Kissei Pharmaceutical Co., Ltd. for CG0070 in Japan and Other Asian Countries
Cold Genesys Announces Name Change to CG Oncology
